Oat globulin peptides regulate antidiabetic drug targets and glucose transporters in Caco-2 cells
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Functional Foods"
DOI: 10.1016/j.jff.2017.12.061
Abstract: Abstract This study clarified the effects of well-characterized oat globulin peptides on antidiabetic drug targets (dipeptidyl peptidase IV [DPP4], α-glucosidase, glucose transporters 2 and 5 [GLUT2, GLUT5]) in Caco-2 cells. Twenty-two peptides with over 8… read more here.
Keywords: drug targets; caco cells; glucose transporters; oat globulin ... See more keywords
Diarylpyrrolone based fluorophore for the selective spectrofluorometric method for determination of Linagliptin antidiabetic drug in pharmaceutical tablets
Sign Up to like & getrecommendations! Published in 2019 at "Microchemical Journal"
DOI: 10.1016/j.microc.2019.05.046
Abstract: Abstract Linagliptin (LNG) is a type 2 antidiabetic drug which belongs to dipeptidyl peptidase 4 inhibitors. In this paper a simple and sensitive spectrofluorometric method was developed and validated for the determination of LNG. The… read more here.
Keywords: diarylpyrrolone based; drug; method; spectrofluorometric method ... See more keywords
Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized, 52‐week, open‐label, parallel‐group trial
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Diabetes Investigation"
DOI: 10.1111/jdi.12759
Abstract: The aim of the present post‐hoc analysis was to investigate the safety and efficacy of liraglutide in combination with one oral antidiabetic drug (OAD) across different OAD classes. read more here.
Keywords: hoc analysis; post hoc; safety efficacy; oral antidiabetic ... See more keywords
Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2021.807548
Abstract: Type 2 diabetes mellitus (T2DM) continues to be a substantial medical problem due to its increasing global prevalence and because chronic hyperglycemic states are closely linked with obesity, liver disease and several cardiovascular diseases. Since… read more here.
Keywords: clinical trials; antidiabetic drug; sglt2 inhibitors; drug ... See more keywords